Journal Article

Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study

Tsukamoto, Tatsuo, Akahori, Toshiyuki, Yamamoto, Ryohei, Narita, Ichiei, Ishimura, Eiji, Mizutani, Makoto, Uchida, Shunya, Ichikawa, Daisuke, Tsuruya, Kazuhiko, Shoji, Tatsuya, Imai, Enyu, Naruse, Tomohiko, Sato, Hiroshi, Tamai, Hirofumi, Kazama, Junichiro J., Isaka, Yoshitaka, Nishio, Saori, Hayashi, Hiroki, Morozumi, Kunio, Goto, Shunsuke, Yamagata, Kunihiro, Katafuchi, Ritsuko, Mimura, Tetsushi, Hasegawa, Hajime, Masutani, Kosuke, Yokoyama, Hitoshi, Saka, Yosuke, Sobajima, Hiroshi, Akai, Yasuhiro, Konta, Tsuneo, Takeda, Asami, Nishino, Tomoya, Nitta, Kosaku, Shirasaki, Arimasa, Hiromura, Keiju, Shigematsu, Takashi, Nagai, Kojiro, Maruyama, Shoichi, Wada, Takashi, Hiramatsu, Takeyuki, Fukunaga, Megumu, Yasuda, Hideo, Sugiyama, Hitoshi

2022

Overview

Background Minimal change disease (MCD) is characterized by a nephrotic syndrome usually steroid-sensitive and a high incidence of relapse of proteinuria. Previous cohort studies have reported conflicting results regarding the association between the time to remission and incidence of relapse. Methods This multicenter prospective cohort study included 102 adult patients with steroid-sensitive MCD or focal segmental glomerulosclerosis from a 5-year cohort study of primary nephrotic syndrome, the Japan Nephrotic Syndrome Cohort Study, who achieved remission of proteinuria within 2 months of immunosuppressive therapy (IST). The association between the time to remission of proteinuria after immunosuppressive therapy and incidence of relapse was assessed using Cox proportional hazards models adjusted for clinically relevant factors. Results Remission was observed at 3–7, 8–14, 15–21, 22–28, and 30–56 days after initiation of immunosuppressive therapy in 17 (16.7%), 37 (36.3%), 21 (20.6%), 13 (12.7%), and 14 (13.7%) patients, respectively. During a median observation period of 2.3 years after the end of the 2nd month after initiation of immunosuppressive therapy, 46 (45.1%) patients relapsed. The time to remission was associated with the incidence of relapse in an inverse U-shaped pattern (multivariable-adjusted hazard ratios [95% confidence intervals] of the time to remission of 3–7, 8–14, 15–21, 22–28, 30–56 days: 1.00 [reference], 1.76 [0.56, 5.51], 6.06 [1.85, 19.80], 5.46 [1.44, 20.64], and 2.19 [0.52, 9.30], respectively). Conclusion The time to remission was identified as a significant predictor of relapse in steroid-sensitive patients.

• Publisher: Springer International Publishing,Oxford University Press
• Subject: Biopsy / Body mass index / Cohort analysis / Creatinine / Ethics / Informed consent / Kidney diseases / Medicine / Medicine & Public Health / Nephrology / original Article / Pediatrics / Performance evaluation / Proteins / Remission (Medicine) / Steroids / Urology